Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Agios Pharma ( (AGIO) ) is now available.
On February 10, 2025, Dr. David P. Schenkein announced his resignation from the Board of Directors of Agios Pharmaceuticals, effective February 28, 2025. Despite stepping down from the Board and its Science and Technology Committee, Dr. Schenkein will continue to play a strategic advisory role, aiding the company’s leadership in advancing clinical development programs.
More about Agios Pharma
Agios Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development of treatments for genetically defined diseases, particularly in the realm of rare diseases and cancer metabolism.
YTD Price Performance: 3.05%
Average Trading Volume: 858,120
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.87B
See more data about AGIO stock on TipRanks’ Stock Analysis page.
